The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2
Open accessPublished version of a preprint
Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Mutations in human leucine-rich repeat kinase 2 (LRRK2), a multi-domain protein containing both a kinase and a GTPase, are a leading cause of the familial form of PD. Pathogenic LRRK2 mutations increase LRRK2 kinase activity. While the bulk of LRRK2 is found in the cytosol, the protein associates with membranes where its Rab GTPase substrates are found, and under certain conditions, with microtubules. Integrative structural studies using single-particle cryo-electron microscopy and in situ cryo-electron tomography (cryo-ET) have revealed the architecture of microtubule-associated LRRK2 filaments, and that formation of these filaments requires LRRK2’s kinase to be in the active-like conformation. However, whether LRRK2 can interact with and form filaments on microtubules in its autoinhibited state, where the kinase domain is in the inactive conformation and the N-terminal LRR domain covers the kinase active site, was not known. Using cryo-ET, we show that full-length human LRRK2 can oligomerize on microtubules in its autoinhibited state. Both WT-LRRK2 and PD-linked LRRK2 mutants formed filaments on microtubules. While these filaments are stabilized by the same interfaces seen in the active-LRRK2 filaments, we observed a new interface involving the N-terminal repeats that were disordered in the active-LRRK2 filaments. The helical parameters of the autoinhibited-LRRK2 filaments are different from those reported for the active-LRRK2 filaments. Finally, the autoinhibited-LRRK2 filaments are shorter and less regular, suggesting they are less stable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Hui, K. Y., Fernandez-Hernandez, H., Hu, J., Schaffner, A., Pankratz, N., Hsu, N.-Y., Chuang, L.-S., Carmi, S., Villaverde, N., Li, X., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7795 · Cited by 384
Flagged first, then by citations
Research works printed but not linked: 43
- Blanca Ramírez, 2017, GTP binding regulates cellular localization of Parkinson’s disease-associated LRRK2, Human Molecular Genetics, 26, 2747, 10.1093/hmg/ddx161 · DOI
- Bonet-Ponce, 2020, LRRK2 mediates tubulation and vesicle sorting from lysosomes, Science Advances, 6, 10.1126/sciadv.abb2454 · DOI
- Castaño-Díez, 2017, Dynamo Catalogue: Geometrical tools and data management for particle picking in subtomogram averaging of cryo-electron tomograms, Journal of Structural Biology, 197, 135, 10.1016/j.jsb.2016.06.005 · DOI
- Croll, 2018, ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps, Acta Crystallographica. Section D, Structural Biology, 74, 519, 10.1107/S2059798318002425 · DOI
- Croxford, 2021, Entropy-regularized deconvolution of cellular cryotransmission electron tomograms, PNAS, 118, 10.1073/pnas.2108738118 · DOI
- Deniston, 2020, Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction, Nature, 588, 344, 10.1038/s41586-020-2673-2 · DOI
- Di Fonzo, 2006, Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease, European Journal of Human Genetics, 14, 322, 10.1038/sj.ejhg.5201539 · DOI
- Di Maio, 2018, LRRK2 activation in idiopathic Parkinson’s disease, Science Translational Medicine, 10, 10.1126/scitranslmed.aar5429 · DOI
- Eguchi, 2018, LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis, PNAS, 115, E9115, 10.1073/pnas.1812196115 · DOI
- Eisenstein, 2023, Parallel cryo electron tomography on in situ lamellae, Nature Methods, 20, 131, 10.1038/s41592-022-01690-1 · DOI
- Fell, 2015, MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition, The Journal of Pharmacology and Experimental Therapeutics, 355, 397, 10.1124/jpet.115.227587 · DOI
- Gloeckner, 2006, The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity, Human Molecular Genetics, 15, 223, 10.1093/hmg/ddi439 · DOI
- Hu, 2023, Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives, European Journal of Medicinal Chemistry, 256, 10.1016/j.ejmech.2023.115475 · DOI
- Kalogeropulou, 2022, Impact of 100 LRRK2 variants linked to Parkinson’s disease on kinase activity and microtubule binding, The Biochemical Journal, 479, 1759, 10.1042/BCJ20220161 · DOI · Paper page
- Kett, 2012, LRRK2 Parkinson disease mutations enhance its microtubule association, Human Molecular Genetics, 21, 890, 10.1093/hmg/ddr526 · DOI
- Mastronarde, 2005, Automated electron microscope tomography using robust prediction of specimen movements, Journal of Structural Biology, 152, 36, 10.1016/j.jsb.2005.07.007 · DOI
- Mastronarde, 2017, Automated tilt series alignment and tomographic reconstruction in IMOD, Journal of Structural Biology, 197, 102, 10.1016/j.jsb.2016.07.011 · DOI
- Monfrini, 2017, Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease, Advances in Neurobiology, 14, 3, 10.1007/978-3-319-49969-7_1 · DOI
- Myasnikov, 2021, Structural analysis of the full-length human LRRK2, Cell, 184, 3519, 10.1016/j.cell.2021.05.004 · DOI
- Pettersen, 2021, UCSF ChimeraX: Structure visualization for researchers, educators, and developers, Protein Science, 30, 70, 10.1002/pro.3943 · DOI
- Ren, 2013, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib, Journal of Medicinal Chemistry, 56, 879, 10.1021/jm301581y · DOI
- Rocha, 2022, LRRK2 and idiopathic Parkinson’s disease, Trends in Neurosciences, 45, 224, 10.1016/j.tins.2021.12.002 · DOI
- Sanz Murillo, 2023, Inhibition of Parkinson’s disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures, Science Advances, 9, 10.1126/sciadv.adk6191 · DOI
- Satake, 2009, Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease, Nature Genetics, 41, 1303, 10.1038/ng.485 · DOI
- Scheres, 2012, RELION: implementation of a Bayesian approach to cryo-EM structure determination, Journal of Structural Biology, 180, 519, 10.1016/j.jsb.2012.09.006 · DOI · Paper page
- Schmidt, 2019, The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain, PNAS, 116, 14979, 10.1073/pnas.1900289116 · DOI
- Schmidt, 2021, Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2, PNAS, 118, 10.1073/pnas.2100844118 · DOI
- Scott, 2017, Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity, Journal of Medicinal Chemistry, 60, 2983, 10.1021/acs.jmedchem.7b00045 · DOI
- Simón-Sánchez, 2009, Genome-wide association study reveals genetic risk underlying Parkinson’s disease, Nature Genetics, 41, 1308, 10.1038/ng.487 · DOI · Paper page
- Snead, 2022, Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubules, Nature Structural & Molecular Biology, 29, 1196, 10.1038/s41594-022-00863-y · DOI · Paper page
- Steger, 2016, Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases, eLife, 5, 10.7554/eLife.12813 · DOI · Paper page
- Tang, 2023, The development and design strategy of leucine-rich repeat kinase 2 inhibitors: promising therapeutic agents for Parkinson’s Disease, Journal of Medicinal Chemistry, 66, 2282, 10.1021/acs.jmedchem.2c01552 · DOI
- Tegunov, 2019, Real-time cryo-electron microscopy data preprocessing with warp, Nature Methods, 16, 1146, 10.1038/s41592-019-0580-y · DOI
- Wang, 2023, Membrane remodeling properties of the Parkinson’s disease protein LRRK2, PNAS, 120, 10.1073/pnas.2309698120 · DOI
- Watanabe, 2020, The in situ structure of parkinson’s disease-linked LRRK2, Cell, 182, 1508, 10.1016/j.cell.2020.08.004 · DOI
- West, 2005, Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, PNAS, 102, 16842, 10.1073/pnas.0507360102 · DOI · Paper page
- Xiromerisiou, 2007, Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson’s disease: identification of two novel LRRK2 variants, European Journal of Neurology, 14, 7, 10.1111/j.1468-1331.2006.01551.x · DOI
- Zhu, 2023, Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2, Science, 382, 1404, 10.1126/science.adi9926 · DOI
- Zhu, 2024, Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM, Cell Discovery, 10, 10.1038/s41421-023-00639-8 · DOI
- Zimprich, 2004, The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval, American Journal of Human Genetics, 74, 11, 10.1086/380647 · DOI
- Zivanov, 2018, New tools for automated high-resolution cryo-EM structure determination in RELION-3, eLife, 7, 10.7554/eLife.42166 · DOI
- Zivanov, 2022, A Bayesian approach to single-particle electron cryo-tomography in RELION-4.0, eLife, 11, 10.7554/eLife.83724 · DOI
- Chen S, Basiashvili T, Hutchings J, Murillo MS, Suarez AV, Louro JA, Leschziner AE, Villa E. 2024. Autoinhibited full-length LRRK2(I2020T) on microtubules with MLi-2. Worldwide Protein Data Bank. · DOI
Metadata
- Authors
- Chen, S., Basiashvili, T., Hutchings, J., Sanz Murillo, M., Villagran Suarez, A., Xiong, E., Alegrio Louro, J., Leschziner, A. E., & Villa, E.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Aligning Science Across Parkinson's (ASAP) Collaborative Research Network
- Department of Molecular Biology, University of California, San Diego
- Corresponding author
- Villa, Elizabeth
- ORCID
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2025-10-31
- Volume
- 13
- ISSN
- 2050-084X (ISSN-L)
- PMC
- PMC12578439
- OpenAlex
- W4402348873
- Cited by
- 1
- References
- 2
- Citations by year
- 2026: 1
- Type
- posted content
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- eLife (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Aligning Science Across Parkinson's (ASAP-000519)
- National Science Foundation (DBI 1920374)
- Jane Coffin Childs Memorial Fund for Medical Research
- American Heart Association
- European Molecular Biology Organization (ALTF 871-2020)
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Advanced Electron Microscopy Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- LRRK2, Parkinson's disease, LRR domain, oligomerization, Rab GTPases, LRRK2 mutations, protein filament structure, helical parameters
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Humans, Microtubules, Protein Binding, Cryoelectron Microscopy, Electron Microscope Tomography, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review